Lilly’s ‘timely’ $2.5B Scorpion deal; GSK pays $1B up front for Idrx

Lilly’s ‘timely’ $2.5B Scorpion Deal; GSK Pays $1B Up Front For Idrx

2 weeks from now

2 days ago  · Joining the dealmaking spree to kick off the 2025 J.P. Morgan Healthcare Conference, Eli Lilly and Co. announced it was picking up an early clinical-stage PI3Kα …

bioworld.com

Eli Lilly In Advanced Talks To Buy US Cancer Biotech For Up To $2.5bn

2 weeks from now

5 days ago  · Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5bn, according to …

skynews.icu

Lilly In Advanced Talks To Buy Cancer Biotech Scorpion For Up To …

2 weeks from now

5 days ago  · Under a proposed deal, Lilly would pay Boston-based Scorpion around $1B upfront followed by up to $1.5B at a later date if certain performance milestones are met, said the …

businessinsider.com

Eli Lilly In Talks To Acquire Scorpion Therapeutics, FT Says ... - MSN

2 weeks from now

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. Eli Lilly (NYSE:LLY) is expected to pay around $1 …

msn.com

Eli Lilly In Advanced Talks To Buy US Cancer Biotech For Up To $2.5bn

2 weeks from now

4 days ago  · As part of the proposed terms, Eli Lilly would pay Boston-based Scorpion about $1bn up front followed by up to $1.5bn at a later date if certain performance milestones were met, …

ft.com

GSK Close To US$1b Deal For Biotech Company IDRx, Bloomberg …

2 weeks from now

6 days ago  · GSK plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology …

theedgemalaysia.com

GSK Is Said To Be Nearing $1B Deal To Acquire U.S. Biotech IDRx

2 weeks from now

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times …

msn.com

Lilly Close To Acquire Cancer Biotech Scorpion Therapeutics For …

2 weeks from now

5 days ago  · Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating …

marketscreener.com

GSK Nears $1 Billion Deal For Biotech Company IDRx - MSN

2 weeks from now

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio.

msn.com

GSK Nears Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

6 days ago  · -- GSK is in advanced discussions to acquire closely held US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the talks. …

marketscreener.com

Caplyta To J&J With $14.6B Buyout Of Intra-Cellular | BioWorld

2 weeks from now

2 days ago  · Shares of Bedminster, N.J.-based Intra-Cellular (NASDAQ:ITCI) were trading at $127.58, up $32.67, or 34%. Lilly’s ‘timely’ $2.5B Scorpion deal; GSK pays $1B up front for …

bioworld.com

GSK Nears $1B Deal To Buy U.S. Biotech IDRx (GSK:NYSE)

2 weeks from now

6 days ago  · British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The …

seekingalpha.com

GSK Nearing $1 Billion Deal To Acquire US Biotech IDRx, FT Reports

2 weeks from now

6 days ago  · GSK Nears Deal to Acquire US Biotech IDRx for Up to $1 Billion Jan. 08: MT GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says ... GSK PLC : …

marketscreener.com